In addition to metformin, glucagon-like peptide-1 (GLP-1) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium–glucose cotransporter 2 (SGLT-2) inhibitors are all excellent choices for people who are at risk of hypoglycemia [23, 37, 39, 40]. Here, DPP4 is linked to Hypoglycemia.